Elicio Therapeutics

Stories

KRAS pancreatic cancer vaccine triggers immune response in 99% of patients, phase 3 trial planned

Developer of camupepimut (ELI-002 7P)

About 90% of pancreatic cancers are driven by mutations in the KRAS gene, long considered undruggable. The experimental vaccine camupepimut (ELI-002 7P) targets seven common KRAS mutations, and 89 of 90 evaluable patients (98.9%) developed KRAS-specific T-cell responses in the phase 2 AMPLIFY-7P trial.

Updated Oct 26